Vinayak Hosagrahara
About Vinayak Hosagrahara
Vinayak Hosagrahara serves as the Executive Director of DMPK at Nimbus Therapeutics, where he has worked since 2021. He has extensive experience in drug metabolism and pharmacokinetics, having held various leadership roles at notable companies including EMD Serono, AstraZeneca, and Bristol-Myers Squibb.
Current Role at Nimbus Therapeutics
Vinayak Hosagrahara serves as the Executive Director of DMPK at Nimbus Therapeutics, a position he has held since 2021. In this role, he oversees drug metabolism and pharmacokinetics strategies, contributing to the development of innovative therapeutics. His leadership is crucial in guiding research initiatives and ensuring the effectiveness of drug candidates.
Previous Experience at Nimbus Therapeutics
Prior to his current position, Vinayak Hosagrahara worked as the Senior Director of DMPK at Nimbus Therapeutics from 2020 to 2021. During this eight-month tenure, he played a significant role in advancing the company's drug development projects through his expertise in DMPK.
Professional Background in Pharmaceutical Industry
Vinayak Hosagrahara has extensive experience in the pharmaceutical industry, having worked at several leading organizations. His career includes positions at EMD Serono, Inc. as Director of NCE Discovery from 2016 to 2020, and at AstraZeneca in various roles, including Director of DMPK and Site Head of DMPK. He also held a position at Novartis Institutes for Biomedical Research as Laboratory Head.
Educational Qualifications
Vinayak Hosagrahara earned his Bachelor of Pharmacy from Bombay College of Pharmacy in Mumbai. He furthered his education at the University of Minnesota, where he obtained a Ph.D. in Medicinal Chemistry. His academic background provides a strong foundation for his work in drug development and pharmacokinetics.
Research Experience
Vinayak Hosagrahara's research experience includes post-doctoral fellowships at the University of Washington and Bristol-Myers Squibb. His work in these roles contributed to his expertise in drug metabolism and pharmacokinetics, enhancing his capabilities in the pharmaceutical research field.